Table 2.
Clinical trials of mRNA vaccines against SARS-CoV-2.
| Name | Sponsoring institution | Target | Phase | mRNA type |
|---|---|---|---|---|
| BNT162b2 | BioNTech/Pfizer | Spike | Phase IV | Non-replicating |
| mRNA-1273 | Moderna | Spike | Phase IV | Non-replicating |
| mRNA-1273.211 | Moderna | Spike | Phase II/III | Non-replicating |
| mRNA-1273.351 | Moderna | Spike | Phase I | Non-replicating |
| mRNA-1273.529 | Moderna | Spike | Phase II | Non-replicating |
| CVnCoV | CureVac AG | Spike | Phase III | Non-replicating |
| CV2CoV | CureVac AG | Spike | Phase I | Non-replicating |
| MRT5500 | Sanofi Pasteur and Translate Bio | Spike | Phase I/II | Non-replicating |
| SW0123 | Stemirna Therapeutics Co., Ltd | Spike | Phase I | Non-replicating |
| PTX-COVID19-B | Providence Therapeutics | Spike | Phase II | Non-replicating |
| ChulaCov19 | Chulalongkorn University | Spike | Phase I/II | Non-replicating |
| mRNA-1283 | ModernaTX, Inc. | RBD+NTD | Phase I | Non-replicating |
| LVRNA009 | LIVERNA THERAPEUTICS INC | RBD | Phase I | Non-replicating |
| DS-5670a | Daiichi Sankyo Co., Ltd. | RBD | Phase I/II | Non-replicating |
| ARCoV | Military Medical Research Institute/ Suzhou Aibo/Watson | RBD | Phase III | Non-replicating |
| ARCT-021 | Arcturus/Duke-NUS | Spike | Phase II | Self-amplifying |
| LNP-nCOVsaRNA | ImperialCollege London/Acuitas | Spike | Phase I | Self-amplifying |
| HDT-301 | SENAI CIMATEC | Spike | Phase I | Self-amplifying |
| LNP-nCOV saRNA-02 vaccine | MRC/UVRI and LSHTM Uganda Research Unit | Spike | Phase I | Self-amplifying |
| CoV2 SAM (LNP) | GlaxoSmithKline | Spike | Phase I | Self-amplifying |
| EXG-5003 | Elixirgen Therapeutics, Inc | RBD | Phase I/II | Self-amplifying |